Loading...

Thursday, February 17th



Miguel Martín, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Chair:
Ángel Guerrero, Instituto Valenciano de Oncología (IVO), Valencia, Spain
16:45 - 17:05ESR1 mutations in estrogen receptor positive breast cancer
Rachel Schiff, Baylor College of Medicine, Houston, USA
17:05 - 17:25Mechanisms of resistance to CDK 4/6 inhibition
Rinath Jeselsohn, Dana-Farber/ Harvard Cancer Institute, Boston,USA
17:25 - 17:45Relevance of PIK3CA mutations in advanced breast cancer
Chi Yan, Vanderbilt University School of Medicine, Nashville, USA
17:45 - 18:15Discussion
Chair:
Luis Costa, Hospital de Santa María, Lisbon, Portugal
18:30 - 18:50Inmunoconjugates for breast cancer: recent advances
Shanu Modi, Memorial Sloan Kettering Cancer Center, New York, USA
18:50 - 19:10TKI inhibitiors in HER2-positive breast cancer
Sandra Swain, Georgetown University Medical Center, Washington D.C., USA
19:10 - 19:30Selective Estrogen Receptor Degraders (SERDs): A New Strategy
for Estrogen Receptor Positive Breast Cancer

Erika P. Hamilton, Tenneessee Oncology, Nashville, USA
19:30 - 20:00Discussion